Loading
A randomised placebo-controlled trial at Tata Memorial found that 2.5 mg of olanzapine daily, a cheap antipsychotic pill already used for chemotherapy nausea, improved appetite and weight gain in patients starting chemotherapy for advanced stomach, lung and hepatopancreatobiliary cancers. A multinational confirmatory trial is needed before guidelines and labels adopt it.
A randomised placebo-controlled trial from Tata Memorial (published in the Journal of Clinical Oncology, 2023) found that 2.5 mg olanzapine daily improved weight gain and appetite in chemotherapy-naive patients with advanced gastric, lung and hepatopancreatobiliary cancers, an area where expensive investigational agents have repeatedly failed. Olanzapine costs cents and is already used for chemotherapy-induced nausea. The proposal is a multinational confirmatory trial with weight, appetite, quality of life and survival endpoints, coupled with a guideline and label strategy so the result reaches patients.
Shares Low-dose olanzapine for cancer anorexia (Tata Memorial), Cachexia, toxicity and the limits of the patient, Tata Memorial Centre, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, Tata Memorial Centre, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Pancreatic ductal adenocarcinoma.